MacroGenics, Inc. (MGNX) Analysts See $-1.10 EPS

April 17, 2018 - By Duane Lopez

Investors sentiment decreased to 1.11 in 2017 Q4. Its down 0.47, from 1.58 in 2017Q3. It is negative, as 14 investors sold MacroGenics, Inc. shares while 31 reduced holdings. 15 funds opened positions while 35 raised stakes. 28.26 million shares or 1.97% more from 27.72 million shares in 2017Q3 were reported.
Art Advsr Limited Com invested in 0.03% or 34,493 shares. Morgan Stanley holds 0% or 74,587 shares in its portfolio. Commercial Bank Of New York Mellon Corporation owns 153,121 shares or 0% of their US portfolio. Tiger Limited Liability invested in 0.38% or 127,967 shares. Sphera Funds Ltd owns 138,700 shares for 0.31% of their portfolio. Goldman Sachs Group Inc holds 65,108 shares or 0% of its portfolio. Tiaa Cref Mgmt Limited Liability Com holds 0% or 80,166 shares in its portfolio. Manufacturers Life Insurance The holds 0% or 26,648 shares. Parallax Volatility Advisers L P reported 5,166 shares. Artal Grp Incorporated reported 0.03% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). Rhenman Partners Asset Management reported 308,604 shares. Point72 Asia (Hong Kong) Ltd owns 69 shares. Tudor Et Al reported 0.01% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). State Board Of Administration Of Florida Retirement Sys holds 17,011 shares or 0% of its portfolio. Rock Springs Cap Management L P reported 225,000 shares.

Since October 25, 2017, it had 0 insider buys, and 8 sales for $1.30 million activity. The insider Karrels James sold $155,000. 10,000 MacroGenics, Inc. (NASDAQ:MGNX) shares with value of $200,000 were sold by Wigginton Jon Marc. $599,436 worth of stock was sold by Cilinski Lynn on Wednesday, February 28.

Analysts expect MacroGenics, Inc. (NASDAQ:MGNX) to report $-1.10 EPS on May, 2.They anticipate $0.02 EPS change or 1.85 % from last quarter’s $-1.08 EPS. After having $2.80 EPS previously, MacroGenics, Inc.’s analysts see -139.29 % EPS growth. The stock increased 2.34% or $0.57 during the last trading session, reaching $24.77. About 118,179 shares traded. MacroGenics, Inc. (NASDAQ:MGNX) has risen 31.18% since April 17, 2017 and is uptrending. It has outperformed by 19.63% the S&P500.

MacroGenics, Inc. (NASDAQ:MGNX) Ratings Coverage

Among 8 analysts covering MacroGenics (NASDAQ:MGNX), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. MacroGenics had 10 analyst reports since October 25, 2017 according to SRatingsIntel. The firm has “Buy” rating by BTIG Research given on Wednesday, October 25. SunTrust maintained the stock with “Buy” rating in Tuesday, January 23 report. Leerink Swann initiated it with “Buy” rating and $3500 target in Friday, April 6 report. On Friday, November 10 the stock rating was maintained by Citigroup with “Neutral”. The firm has “Buy” rating by BTIG Research given on Friday, January 19. Morgan Stanley maintained it with “Equal-Weight” rating and $26 target in Wednesday, March 14 report. Leerink Swann maintained the stock with “Buy” rating in Wednesday, October 25 report.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company has market cap of $1.05 billion. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It currently has negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

MacroGenics, Inc. (NASDAQ:MGNX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: